Vicarious Surgical INC

Vicarious Surgical Inc. has filed a Form 8-K announcing the approval of a general assignment for the benefit of creditors and a plan of dissolution, leading to the resignation of its board and termination of key executives.

Vicarious Surgical Inc. announced the resignation of Chief Financial Officer Sarah Romano, effective July 22, 2026.

Vicarious Surgical Inc. announced that its stockholders approved an amendment to its Certificate of Incorporation to effect a reverse stock split.

Vicarious Surgical Inc. announced executive salary reductions for its President and CTO, coinciding with its delisting from the NYSE.

Vicarious Surgical Inc. announced its Class A common stock will be delisted from the NYSE due to falling below the minimum market capitalization requirement, with trading suspended and a move to the OTCID market tier.

Vicarious Surgical Inc. has updated the severance and change-in-control agreements for its CEO, Stephen From, and CFO, Sarah Romano, enhancing their termination benefits.

Vicarious Surgical Inc. reported a net loss of $7.3 million for the first quarter of 2026, a significant reduction from the prior year's $15.4 million loss, driven by substantial decreases in operating expenses.

Vicarious Surgical Inc. reported a reduced net loss for Q3 2025, but faces substantial doubt about its ability to continue as a going concern despite a recent $5.2 million capital raise.

Vicarious Surgical reported continued net losses and significant doubt about its ability to continue as a going concern, while addressing NYSE listing non-compliance.

Vicarious Surgical faces NYSE compliance issues and continues product development with a net loss of $15.39 million for Q1 2025.

Vicarious Surgical reported a net loss of $17.1 million for the third quarter of 2024, an improvement compared to the $15.7 million loss in the same period last year, driven by reduced operating expenses.

Vicarious Surgical's Q2 2024 results show a reduced net loss compared to the same period last year, driven by lower operating expenses.

Vicarious Surgical's 10-K filing details the structure of its capital stock, including Class A and Class B common stock, preferred stock authorization, and warrant information.

Vicarious Surgical's 10-K filing outlines its capital structure, including Class A and Class B common stock, preferred stock, and warrants, while also detailing its regulatory strategy for its surgical robot.

Vicarious Surgical's President and Director, Adam David Sachs, sold 942 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Vicarious Surgical Inc.'s Chief Technology Officer, Sammy Khalifa, sold 754 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Vicarious Surgical Inc. President Adam Sachs sold 463 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Vicarious Surgical's Chief Technology Officer, Sammy Khalifa, sold 239 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Vicarious Surgical's Chief Technology Officer, Sammy Khalifa, sold 653 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Vicarious Surgical Inc.'s President, Adam David Sachs, sold 816 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Vicarious Surgical Inc. is seeking stockholder approval for a reverse stock split to boost its share price and facilitate a potential Nasdaq Capital Market listing following its delisting from the NYSE.

Vicarious Surgical Inc. is holding a special meeting on January 9, 2026, to seek stockholder approval for the exercise of common warrants to purchase up to 2,300,000 shares of Class A common stock.

Vicarious Surgical Inc. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

Vicarious Surgical is holding its 2025 annual meeting virtually on June 27, 2025, to elect directors, approve an amendment to the 2021 Equity Incentive Plan, and ratify the appointment of Deloitte & Touche LLP as its independent auditor.

Vicarious Surgical Inc. has filed a definitive proxy statement with the SEC.

Vicarious Surgical is seeking stockholder approval for a reverse stock split to maintain its NYSE listing and an amendment to its equity incentive plan to attract and retain key personnel.

Innovation Endeavors III LP and Dror Berman have reduced their beneficial ownership in Vicarious Surgical Inc. to below 5% after a series of stock sales.